- $1.93bn
- $676.81m
- $548.51m
HUTCHMED Completes Enrollment of Phase III Trial
Brief: Hutchmed (China) Updates FY25 Guidance For Oncology/Immunology Consol Rev To $270M - $350M
HUTCHMED (China) Posts H1 Net Income USD 455 Million
2025 Interim Results
Factbox: CK Hutchison: Global conglomerate caught in US-China trade spat
Hutchmed To Announce 2025 Half: Year Results
Grant of Share Options and Awards under LTIP
Hutchmed Hits 2: month high on drug application for kidney cancer treatment
HUTCHMED and Innovent Announce NDA Acceptance
Brief: HUTCHMED (China) Says NDA Acceptance In China For Fruquintinib Combination With Sintilimab
HUTCHMED Highlights SACHI Phase III Data at ASCO
HUTCHMED Highlights Data to be Presented at ASCO
Hutchmed: Data to be Presented at AACR 2025
HUTCHMED Completes Enrollment of Phase II Study
2024 Annual Report and Notice of AGM
Brief: Hutchmed (China) Gets NMPA Conditional Approval For Tazverik® (Tazemetostat)
Factbox: CK Hutchison: a global conglomerate caught in US-China trade spat
Retirement of Independent Non-executive Directors
Brief: Hutchmed China Ltd says Savannah Phase II trial shows high response rates with Savolitinib plus Tagrisso